Dr Kopetz on the Phase 3 BREAKWATER Trial in Frontline Metastatic CRC

Scott Kopetz, MD, PhD, FACP, deputy chair and professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, leader, Department of Cancer Center Support Grant, GI Program, TRACTION Medical Director, Division of Therapeutics Discovery Division, and Associate Vice President for Translational Integration, The University of Texas MD Anderson Cancer Center, discusses findings from the phase 3 BREAKWATER study (NCT04607421) of frontline encorafenib (Braftovi) plus cetuximab (Erbitux) with or without chemotherapy in BRAF V600E–mutated metastatic colorectal cancer.